Enzon Pharmaceuticals, Inc. (ENZN)

Enzon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0.03	0.7	0.05	0.21
Revenue Growth (YoY)	-	-	-96.29%	1248.08%	-74.88%	-97.01%
Gross Profit	0	0	0.03	0.7	0.05	0.21
Selling, General & Admin	1.09	1.04	1.06	1.17	1.36	1.18
Other Operating Expenses	0	0	0.65	0.01	0	0
Operating Expenses	1.09	1.04	1.06	1.17	1.36	1.18
Operating Income	-1.09	-1.04	-1.03	-0.47	-1.31	-0.97
Interest Income	2.46	2.26	0.65	0.01	0	0
Interest Expense	0.45	0	-0.65	0	0	0
Other Expense / Income	-0.45	-	0.65	-	-0	-
Pretax Income	1.38	1.22	-0.39	-0.46	-1.3	-0.97
Income Tax	-0.12	-0.16	-0.2	0.01	0.01	0.01
Net Income	1.5	1.37	-0.19	-0.47	-1.31	-0.98
Net Income Growth	281.63%	-	-	-	-	-
Shares Outstanding (Basic)	74	74	74	74	51	44
Shares Outstanding (Diluted)	74	74	74	74	51	44
Shares Change	-	-	-	45.23%	15.57%	-
EPS (Basic)	0.00	0.02	-0.00	-0.01	-0.03	-0.02
EPS (Diluted)	0.00	0.02	-0.00	-0.01	-0.03	-0.02
EPS Growth	25.00%	-	-	-	-	-
Free Cash Flow	1.39	1.31	-0.66	-0.5	-0.38	6.91
Free Cash Flow Per Share	0.02	0.02	-0.01	-0.01	-0.01	0.16
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-3969.23%	-66.90%	-2509.62%	-470.05%
Profit Margin	-	-	-715.38%	-66.90%	-2521.15%	-472.95%
Free Cash Flow Margin	-	-	-2534.62%	-71.47%	-730.77%	3335.75%
Effective Tax Rate	-8.72%	-12.82%	-	-	-	-
EBITDA	-1.09	-1.04	-1.03	-0.47	-1.31	-0.97
EBITDA Margin	-	-	-3969.23%	-66.90%	-2509.62%	-470.05%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.